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ABSTRACT 
Introduction Viral acute respiratory infections (ARIs) 
cause substantial child morbidity. Sensitive molecular-
based assays aid virus detection, but the clinical 
significance of positive tests remains uncertain as some 
viruses may be found in both acutely ill and healthy 
children. We describe disease-pathogen associations of 
respiratory viruses and quantify virus-specific attributable 
risk of ARIs in healthy children during the first 2 years of 
life.
Methods One hundred fifty-eight term newborn babies 
in Brisbane, Australia, were recruited progressively into 
a longitudinal, community-based, birth cohort study 
conducted between September 2010 and October 2014. 
A daily tick-box diary captured predefined respiratory 
symptoms from birth until their second birthday. Weekly 
parent-collected nasal swabs were batch-tested for 17 
respiratory viruses by PCR assays, allowing calculation 
of virus-specific attributable fractions in the exposed 
(AFE) to determine the proportion of virus-positive 
children whose ARI symptoms could be attributed to that 
particular virus.
Results Of 8100 nasal swabs analysed, 2646 (32.7%) 
were virus-positive (275 virus codetections, 3.4%), 
with human rhinoviruses accounting for 2058/2646 
(77.8%) positive swabs. Viruses were detected in 
1154/1530 (75.4%) ARI episodes and in 984/4308 
(22.8%) swabs from asymptomatic periods. Respiratory 
syncytial virus (AFE: 68% (95% CI 45% to 82%)) and 
human metapneumovirus (AFE: 69% (95% CI 43% to 
83%)) were strongly associated with higher risk of lower 
respiratory symptoms.
Discussion The strong association of respiratory 
syncytial virus and human metapneumovirus with ARIs 
and lower respiratory symptoms in young children 
managed within the community indicates successful 
development of vaccines against these two viruses 
should provide substantial health benefits.
INTRODUCTION
Viral acute respiratory infections (ARIs) are a 
common cause of morbidity in children, either on 
their own or in synergy with bacterial pathogens.1 
Virus-positive ARIs early in life are associated with 
developing wheeze and asthma during childhood 
and adolescence.2 Community-based studies from 
the 1950s to 1960s examining the aetiology of ARIs 
by traditional laboratory detection methods remain 
the template for understanding childhood respira-
tory virus epidemiology.3 Advances in molecular 
diagnostics, including PCR testing, have improved 
virus detection in those with ARIs.4 However, this 
increased test sensitivity has also resulted in viruses 
being detected in asymptomatic individuals.4 5 The 
clinical significance of finding respiratory viruses 
is not always straightforward, and a better under-
standing of the proportion of infections that are 
symptomatic for individual viruses is needed.
The attributable fraction in the exposed (AFE) 
provides information about the percentage of cases 
among exposed individuals that can be attributed 
to the exposure. In our study, the AFE measures 
the percentage of ARIs in virus-positive children 
attributable to that particular virus. The AFE does 
not inform on the aetiology at an individual level, 
but is a key population-level metric for interpreting 
positive specimen results. It assists with estimation 
of the true burden of disease, thus guiding preven-
tative strategies for respiratory infections, such as 
immunisation. Virus-specific AFE estimates for ARI 
in children are reported infrequently, with most 
studies reporting AFEs having important meth-
odological limitations. Except for one community 
Key messages
What is the key question?
 ► What is the attributable risk for symptoms of 
acute respiratory infections (ARIs) when specific 
respiratory viruses are detected by PCR assays 
in nasal swab samples collected weekly from 
otherwise healthy young children?
What is the bottom line?
 ► Attribution for ARIs by specific viruses was 
strongest for respiratory syncytial virus and 
human metapneumovirus in young children 
with lower respiratory tract infections, while 
among DNA viruses tested, only adenoviruses 
were significantly associated with an increased 
risk of symptoms.
Why read on?
 ► The virus-specific attributable risk of ARIs is 
a population-level metric to inform causal 
inference in the aetiology of ARIs and 
provides quantitative estimates of the relative 
proportions of virus-associated ARIs in the 
community, yielding important insights for 
prioritising public health interventions.
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study,5 these investigations recruited either highly selected hospi-
talised children or outpatients as study cases,6–8 or used controls 
from outpatient clinics.6 7 A meta-analysis of 23 studies that 
calculated virus-specific AFEs included 22 studies employing 
hospital-based case ascertainment and only three using commu-
nity-based controls.9 Other studies comparing symptomatic and 
asymptomatic groups calculated odds ratios (ORs),10–12 or rela-
tive risks,13 without calculating AFEs. Moreover, several studies 
focused solely either on specific viruses10 12 or outcomes.6 11–13
Longitudinal, community-based studies employing sensitive 
molecular-based assays with regular and frequent sampling, 
irrespective of illness, are best suited to explore the relation-
ship between respiratory virus detections and ARI symptoms, 
especially as they represent most ARI episodes. The aim of our 
study was to examine the disease-pathogen associations of respi-
ratory viruses in infants participating in a community-based birth 
cohort project14 and to calculate their virus-specific AFE values.
METHODS
Study population
The Observational Research in Childhood Infectious Diseases 
(ORChID) project ( clinicaltrials. gov: NCT01304914) is an 
observational, longitudinal community-based birth cohort study 
of ARI episodes in children until their second birthday.14 Partic-
ipants were able to leave the study temporarily (such as during 
family holidays) and rejoin at a later date. It was conducted in 
the subtropical city of Brisbane, Australia (latitude 27° South, 
average monthly maximum temperature range 22°C–30°C, 
maximum rainfall in December-February, population 2.2 million) 
between September 2010 and October 2014. Parents consented 
antenatally for their child’s participation. For enrolment, infants 
needed to be healthy, without congenital abnormalities or under-
lying chronic disorders, and to be born at term (36–42 weeks). 
Recruitment was progressive over 2 years at one of two metro-
politan hospitals (one private and one government-funded). 
Detailed methods of recruitment, study design and sample and 
data collection are described elsewhere.14 The Children’s Health 
Queensland, Royal Brisbane and Women’s Hospital, and The 
University of Queensland Human Research Ethics Committees 
approved the study.
Sociodemographic and clinical characteristics
Following recruitment, parents provided their sociodemographic 
and health history, pregnancy and birth details. Telephone inter-
views were conducted every 3 months to update immunisation, 
feeding and childcare attendance details. Childcare was cate-
gorised as formal (regulated care outside the child’s home) or 
informal (non-regulated care provided by family or friends).15 
The duration of exclusive breast feeding was from birth to the 
introduction of either any milk formula or solids.
Symptom data collection
Parents were trained to recognise respiratory symptoms and 
provided with diary cards designed in a tick-box format and listed 
with predefined respiratory symptoms or diagnoses to be completed 
daily and returned by regular mail monthly. The diary cards were 
modified from a prior study16 and used successfully elsewhere.17
Virus detection
Viruses were identified from parent-collected anterior nose swabs at 
the infant’s birth, and weekly thereafter.18 Specimens were mailed 
Figure 1 Submission of nasal swabs and symptom diaries from participants in the Observational Research in Childhood Infectious Diseases 
study. Ct, cycle threshold; ERV-3, endogenous retrovirus-3.
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to the laboratory, taking a median of 3 (IQR 2–4) days, and where 
they were processed and stored at −80°C until further analysis.14 19
Swabs were batch-tested for 17 respiratory viruses: human rhino-
virus (HRV), influenza A and B (IFV-A, IFV-B), respiratory syncytial 
virus A and B (RSV-A, RSV-B), parainfluenza viruses 1–3 (PIV-1, 
PIV-2, PIV-3), human coronaviruses (HCoV) OC43, NL63, 229E 
and HKU1, human metapneumovirus (HMPV), adenovirus (AdV), 
human polyomaviruses WU (WU-PyV) and KI (KI-PyV) and human 
bocavirus-1 (HBoV-1), using previously validated real-time PCR 
assays.14 Details of sample collection, processing, PCR assay param-
eters, quality control measures and HRV typing into species A, B 
and C are outlined in the online supplementary text and E-table 
1. Specimen quality was assessed by testing for a marker of human 
genomic DNA, endogenous retrovirus-3 (ERV-3).20 Swabs with 
ERV-3 cycle-threshold (Ct) values >38 (including undetectable Ct 
values) were deemed to be of lesser quality and excluded from parts 
of the analysis.21
Definitions
New virus detection episode
When a new virus (different virus or new species/subtype of the 
same genus or species, respectively) was detected in a swab by 
PCR testing, or the same virus was detected after at least two 
negative intervening swabs, or the same virus was detected at 
least 30 days from the last positive swab.
Symptomatic new virus detection episode
When symptoms were reported 7 days before or 7 days after 
detecting a new virus.
ARI episode
ARI was defined as a new episode of respiratory symptoms of the 
upper and/or lower respiratory tracts demarcated by a window 
of ≥3 symptom-free days.17 22
Upper respiratory tract infection
Parent-reported runny nose/nasal congestion, dry cough or 
doctor-diagnosed otitis media.22
Lower respiratory tract infection
Parent-reported rattly breathing, moist cough, shortness of 
breath, wheeze or doctor-diagnosed pneumonia.22
ARIs were subcategorised hierarchically as either a lower 
respiratory tract infection (LRTI) or upper respiratory tract 
infection (URTI), respectively.
Analysis
The incidence rate of single new virus detection episodes (VDEs) 
per 100 child-years was calculated using Poisson regression. To 
account analytically for the differing lengths of time children 
remained in the study, the natural logarithm of the number of 
swabs returned was included in the model as an offset. Swabs 
were removed from incidence rate calculations for individual 
viruses when the participant was not at risk of a new VDE (a 
positive consecutive swab following the initial positive swab, and 
two swabs after the last positive swab, as per our definition of a 
new VDE), or the swabs were of lesser quality (to avoid underes-
timating incidence rates).21 When calculating incidence rates for 
‘any virus’, we assumed children were at risk of being positive 
for new viruses in every swab.
The virus-specific risk and AFE of single VDEs in cases of ARI 
and LRTI were estimated using a generalised linear model with 
binomial family and log link. Robust variance estimates were 
calculated using sandwich estimators to account for repeated 
measures within children. We analysed LRTIs separately as chil-
dren with these infections are more likely to visit family physi-
cians, present to hospital and receive antibiotics.22 The AFE was 
Table 1 Characteristics of children enrolled in the Observational 
Research in Childhood Infectious Diseases study
Characteristic (n=158 unless stated) Frequency (%) or mean (±SD)
Sex (male) 75 (47.5%)
Gestational age (weeks) 39.8 (±1.3)
Birth weight (g) 3530.8 (±430.4)
Delivery
  Vaginal 107 (67.7%)
Birth order (maternal)
  First born 106 (67.1%)
Parental mean age
  Mother (years) (n=157) 31.8 (±4.6)
Family history of asthma or eczema
  Mother 50 (31.6%)
  Father 44 (27.8%)
  Sibling 15 (9.5%)
  First-degree relative with asthma or eczema 83 (52.5%)
Smoke exposure at birth
  Mother (n=156) 5 (3.2%)
  Other householder (n=155)* 17 (11.0%)
Maternal educational status (n=157)
  Primary school 5 (3.2%)
  High school 15 (9.6%)
  Diploma/certificate 38 (24.2%)
  University or higher university degree 99 (63.1%)
Household income (n=155)†
  Lowest quarter 0
  Lower quarter 17 (11.0%)
  Higher quarter 52 (33.5%)
  Highest quarter 86 (55.5%)
Child immunisation status to 18 months (n=154)‡
  Fully immunised 141 (91.6%)
Exclusive breast feeding
  At birth (n=149) 142 (95.3%)
  At 3 months (n=142) 97 (68.3%)
  At 6 months (n=133) 5 (3.8%)
Childcare
  At 6 months (n=133) 33 (24.8%)
  At 9 months (n=123) 48 (39.0%)
  At 12 months (n=115) 72 (62.6%)
  At 15 months (n=110) 87 (79.1%)
*Includes two single parent households.
†Income categories based on Australian Bureau of Statistics income quartiles (quartile 1: 
<$A26 000; quartile 2: $A26 000–$A67 499; quartile 3: $A67 500–$A114 999; quartile 4: 
≥$A115 000).
‡11/154 (7.1%) infants did not receive a full course of rotavirus vaccines because they 
presented for immunisation outside of required age limits; 2 children had chickenpox 
diagnosed before the varicella vaccine could be administered at the scheduled age of 
18 months, but were up-to-date for all other vaccines; another 2 children withdrew early 
and information was unavailable on their later immunisations. Influenza vaccines are not 
part of the national Australian infant immunisation schedule. Only 7 children received the 
influenza vaccine in the first 2 years of life.
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calculated as 100%×(1−RR−1), where risk ratio (RR) is the 
proportion of children positive for a virus with ARI symptoms, 
divided by the proportion of children negative for the virus who 
have ARI symptoms (see online supplementary text 2). Only 
virus-negative swabs of lesser quality (Ct >38) were excluded in 
these analyses of association, as swab quality of positive swabs 
did not modify the association between VDEs and ARI symp-
toms (see online supplementary E-table 2).
The association between potential risk factors (age, sex, type of 
delivery, gestational age at birth, season, family history of asthma or 
eczema, tobacco smoke exposure, household size, maternal educa-
tion status, mode of feeding, category of childcare attendance) 
and symptomatic and asymptomatic virus detection was examined 
using mixed-effects logistic regression with the child entered as a 
random effect to account for repeated measurements within chil-
dren. Both univariable and multivariable analyses were conducted. 
Breast feeding and childcare attendance were analysed as time-
varying variables. Multivariable models included all the above risk 
factors with no forward or backward selection. Only virus-negative 
Table 2 Respiratory viruses detected in 8100 high-quality nasal swabs collected from 157 infants from the Observational Research in Childhood 
Infectious Diseases (ORChID) birth cohort in the first 2 years of life. Incidence rates/100 child-years presented overall, and for the first and second 
years of life separately
Virus
Virus-positive swabs
New virus detections
N=1520*
New virus detection 
episodes/100 child-years
(overall year mean)
New virus detection 
episodes/100 child-years
(first year)
New virus detection 
episodes/100 child-years
(second year)
n (%) n (%) Mean (95% CI) Mean (95% CI) Mean (95% CI)
All HRV† 2058 (25.4) 1012 (66.6) 1002 (942 to 1066) 770 (703 to 842) 1354‡ (1245 to 1472)
HRV-A 702 (8.7) 440 (28.9) 323 (295 to 355) 258 (224 to 297) 409 (361 to 464)
HRV-B 154 (1.9) 97 (6.4) 64 (53 to 78) 60 (45 to 79) 69 (52 to 92)
HRV-C 635 (7.8) 495 (32.6) 363 (332 to 396) 295 (259 to 336) 448 (398 to 505)
IFV-A 12 (0.1) 12 (0.8) 7.7 (4.4 to 13.6) 4.7 (1.8 to 12.5) 11.5 (5.7 to 22.9)
IFV-B 2 (0.0) 2 (0.1) 1.3 (0.3 to 5.2) 1.2 (0.2 to 8.3) 1.4 (0.2 to 10.1)
PIV-1 7 (0.1) 7 (0.5) 4.5 (2.2 to 9.5) 2.3 (0.6 to 9.3) 7.2 (3.0 to 17.2)
PIV-2 4 (0.0) 4 (0.3) 2.6 (1.0 to 6.9) 1.2 (0.2 to 8.3) 4.3 (1.4 to 13.3)
PIV-3 59 (0.7) 56 (3.7) 36.5 (28.1 to 47.4) 27.1 (18.0 to 40.8) 47.8 (34.0 to 67.3)
RSV-A 69 (0.9) 58 (3.8) 37.9 (29.3 to 49.0) 30.7 (20.9 to 45.1) 46.4 (32.8 to 65.6)
RSV-B 22 (0.3) 20 (1.3) 12.9 (8.3 to 20.1) 8.2 (3.9 to 17.2) 18.7 (10.9 to 32.2)
HCoV-OC43 51 (0.6) 42 (2.8) 27.3 (20.2 to 37.0) 18.8 (11.5 to 30.7) 39.1 (26.8 to 57.0)
HCoV-NL63 56 (0.7) 40 (2.6) 26.0 (19.1 to 35.5) 18.8 (11.5 to 30.7) 37.7 (25.6 to 55.3)
HCoV-229E 14 (0.2) 9 (0.6) 5.8 (3.0 to 11.2) 4.7 (1.8 to 12.5) 7.2 (3.0 to 17.2)
HCoV-HKU1 34 (0.4) 28 (1.8) 18.2 (12.5 to 26.3) 10.5 (5.5 to 20.3) 27.4 (17.5 to 43.0)
HMPV 27 (0.3) 23 (1.5) 14.9 (9.9 to 22.4) 12.9 (7.1 to 23.3) 17.2 (9.8 to 30.4)
AdV 104 (1.3) 80 (5.3) 52.6 (42.2 to 65.4) 47.6 (34.9 to 64.9) 58.3 (42.8 to 79.5)
WU-PyV 101 (1.2) 60 (3.9) 39.3 (30.5 to 50.6) 16.5 (9.8 to 27.8) 67.6 (50.6 to 90.2)
KI-PyV 168 (2.1) 84 (5.5) 55.7 (45.0 to 68.9) 51.6 (38.3 to 69.5) 60.4 (44.5 to 82.1)
HBoV-1 137 (1.7) 90 (5.9) 59.6 (48.5 to 73.3) 47.8 (35.1 to 65.2) 73.8 (55.9 to 97.4)
Any virus§ 2646 (32.7) 1520 (18.8) 978 (930 to 1029) 794 (736 to 856) 1206 (1127 to 1290)
Codetections§ 275 (3.4) 237 (15.6) 147 (130 to 168) 117 (96 to 142) 184 (155 to 219)
*Includes codetections.
†666 HRV (28.5%) positive samples could not be sequenced primarily because of low viral loads.
‡The rate of HRV new VDEs and the mean incidence of HRV new VDEs may equal or exceed the total rate of all new VDEs depending on the denominator after all swabs with 
cycle-threshold values >38 are excluded.
§Days at risk were not removed from the denominator as an infant could be at risk of being positive for other viruses in every swab.
HBoV-1, human bocavirus-1; HCoV, human coronavirus; HMPV, human metapneumovirus; HRV, human rhinovirus; IFV, influenza virus; KI-PyV, KI polyomavirus; PIV, parainfluenza 
virus; RSV, respiratory syncytial virus; VDE, virus detection episode; WU-PyV, WU polyomavirus. 
Figure 2 Incidence rate of new virus detection episodes per child-
month by age and type of infection (n=151). VDE, virus detection 
episode.
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lesser quality swabs were excluded in these analyses. As it was 
not possible to determine individual virus contributions to ARI 
symptoms during virus codetections, samples with more than one 
virus detected were analysed descriptively (see online supplemen-
tary E-table 3). Data were analysed using Stata V.12.1 (StataCorp, 
College Station, Texas, USA).
RESULTS
Cohort characteristics
Of 891 potential participants approached, 165 (18.5%) eligible 
singleton infants from 163 families were enrolled (two fami-
lies enrolled two siblings) (figure 1). Seven were excluded 
subsequently; one from ineligibility (born <36 weeks) and six 
for failing to provide any swabs. Of the remaining children, 
158 provided 11 125 swabs (figure 1; 68.3% of maximum 
expected; median 84.5, range 1–104) from birth until their 
second birthday, and 154 infants provided 87 547 child-days of 
symptom diaries (77.9% of maximum expected days; median 
726 (range 1–730 days)) with 67% followed until at least age 
23 months (see online supplementary E-figure). One or more 
respiratory symptoms were recorded on 16 877 (19.3%) days, 
and corresponded to 1641 discrete ARI episodes.
Demographic and social characteristics are reported in 
table 1. Compared with the general population of Brisbane 
and the state of Queensland, study children were from smaller 
families of advantaged backgrounds (see online supplementary 
E-table 4).
Virus detections
When calculating incidence rates, of the 11 192 total swabs 
submitted by all children, 3025 (27.2%) lesser-quality swabs 
(346 virus-positive and 2679 virus-negative) were removed from 
the analyses, as were 67 swabs submitted after the child’s second 
birthday, leaving 8100 swabs from 157 infants (figure 1). Overall, 
Table 3 Acute respiratory infections and asymptomatic single new virus detections, risk ratios and attributable fractions by respiratory virus in 151 
children from the ORChID birth cohort (n=8202)
Virus
ARI-associated single new virus 
detections
N=3894 swabs
Asymptomatic single new virus 
detections
N=4308 swabs
Risk ratio*
(95% CI); P value
Attributable fraction in the 
exposed (%, 95% CI)†
n (%) n (%)
Single new detections 
  All HRV 679 (17.4)‡ 328 (7.6) 1.5 (1.4 to  1.6); <0.001 34 (29 to  38)
  HRV-A 289 (7.4) 122 (2.8) 1.5 (1.4 to  1.6); <0.001 34 (28 to  39)
  HRV-B 49 (1.3) 41 (1.0) 1.2 (0.9 to  1.4);  0.17 14 (−6 to  30)
  HRV-C 328 (8.4) 137 (3.2) 1.5 (1.4 to  1.7); <0.001 35 (30 to  40)
  IFV-A 9 (0.2) 2 (0.0) 1.7 (1.3 to  2.3); <0.001 42 (23 to  57)
  IFV-B 2 (0.1) 2 (0.0) 1.1 (0.4 to  2.8);  0.90 6 (− 150 to  64)
  PIV-1 6 (0.2) 1 (0.0) 1.8 (1.3 to  2.5); <0.001 45 (26 to  59)
  PIV-2 3 (0.1) 0 (0.0) n/c n/c
  PIV-3 32 (0.8) 11 (0.3) 1.5 (1.3 to  1.9); <0.001 35 (21 to  46)
  RSV-A 29 (0.7) 14 (0.3) 1.4 (1.2 to  1.7); <0.001 30 (16 to  42)
  RSV-B 19 (0.5) 3 (0.1) 1.8 (1.5 to  2.2); <0.001 46 (35 to  54)
  HCoV-OC43 26 (0.7) 8 (0.2) 1.6 (1.3 to  2.0); <0.001 38 (25 to  50)
  HCoV-NL63 27 (0.7) 8 (0.2) 1.6 (1.3 to  2.0); <0.001 37 (21 to  49)
  HCoV-229E 3 (0.1) 4 (0.1) 0.9 (0.4 to  2.2);  0.83 −10 (−161 to  54)
  HCoV-HKU1 12 (0.3) 10 (0.2) 1.2 (0.8 to  1.7);  0.42 14 (− 24 to  40)
  HMPV 12 (0.3) 4 (0.1) 1.6 (1.2 to  2.1);  0.001 37 (16 to  53)
  AdV 28 (0.7) 16 (0.4) 1.4 (1.1 to  1.7);  0.008 29 (12 to  42)
  WU-PyV 16 (0.7) 15 (0.3) 1.1 (0.8 to  1.6);  0.62 9 (− 31 to  36)
  KI-PyV 23 (0.6) 34 (0.8) 0.9 (0.6 to  1.2);  0.37 −17 (−65 to  17)
  HBoV-1 35 (0.9) 31 (0.7) 1.1 (0.9 to  1.4);  0.30 11 (− 12 to  29)
  Any virus 961 (24.6) 491 (11.4) 1.5 (1.4 to  1.6); <0.001 35 (31 to  38)
New codetections§
  ≥2 viruses 168 (4.3) 62 (1.4) 1.6 (1.4 to  1.7); <0.001 37 (30 to  42)
Statistically significant risk ratios and attributable fractions have been highlighted in bold.
*Adjusted for repeated measures within children using sandwich estimators.
†CI for attributable fractions were calculated from CI for corresponding risk ratios.
‡Individual HRV species do not add up to ‘all HRV’ detections because of a combination of more than one HRV species detected within the same ARI episode, or single new virus 
detection episodes where HRV-positive specimens could not be sequenced.
§Includes 219 (160 symptomatic) new codetections and another 11 codetections with 2 and 3 viruses codetected, respectively where at least 1 codetected virus was a new 
detection.
ARI, acute respiratory infection; AdV, adenovirus; HBoV-1, human bocavirus-1; HCoV, human coronavirus; HMPV, human metapneumovirus; HRV, human rhinovirus; IFV, influenza 
virus; KI-PyV, KI polyomavirus; n/c, not calculable as there were no cases in the asymptomatic group; PIV, parainfluenza virus; RSV, respiratory syncytial virus; WU-PyV, WU 
polyomavirus. 
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2646/8100 (32.7%) swabs were positive for respiratory viruses 
(table 2), of which 1520 were new VDEs.
The incidence of new VDEs increased in the first 9 months of 
life, with symptomatic episodes dominating after 6 months of age 
(figure 2). There was an overall incidence rate of 978 new VDEs 
per 100 child-years (95% CI 930 to 1029, table 2). More than one 
virus was detected in 275/8100 (3.4%) specimens. HRV was the 
most commonly detected virus (2058/2646 detections, 77.8% of 
all positive detections, mean rate of 1002 new VDEs per 100 child-
years, 95% CI 942 to 1066), followed by HBoV-1 (60 new VDEs 
per 100 child-years, 95% CI 49 to 73) and KI-PyV (56 new VDEs 
per 100 child-years, 95% CI 45 to 69) (table 2).
Virus-positive ARIs and asymptomatic episodes
When considering virus-positive ARIs and asymptomatic 
episodes, we retained 346 virus-positive swabs with ERV-3 
Ct values >38, but removed a further 244 swabs with missing 
symptom data, to give a final dataset of 8202 swabs from 151 
participants (3 participants submitted swabs of high or no Ct 
values or swabs with no corresponding symptom data before 
withdrawing early in the study) (tables 3–5).
Of 8202 swabs, 3894 (47.5%) were taken during symptomatic 
periods and 4308 (52.5%) from asymptomatic periods. Of all 
swabs taken any time during symptomatic periods, 1903/3894 
(48.9%) were positive for a virus, and 1120/3894 (28.8%) were 
new VDEs. Overall, 984/4308 (22.8%) swabs taken during 
asymptomatic periods were positive for a virus, of which 562 
(57.1%) were new VDEs and 491/562 (87.4%) were new single 
virus detections (tables 3 and 4).
Table 3 shows that for new VDEs involving only single viruses, 
HRV-A, HRV-C, IFV-A, PIV-3, RSV-A, RSV-B, HCoV-OC43, 
HCoV-NL63, HMPV, and AdV had statistically significant, posi-
tive AFE values, indicating they were significantly more often 
associated with ARI episodes than asymptomatic periods. In 
Table 4 Lower respiratory tract infections and asymptomatic single new virus detections, risk ratios and attributable fractions by respiratory virus 
in 151 children from the ORChID birth cohort (n=5267 swabs)
Virus
LRTI-associated single new 
virus detections
n=959 swabs
Asymptomatic single new virus 
detections
n=4308 swabs
Risk ratio*
(95% CI); P value
Attributable fraction in the 
exposed (%, 95% CI)†
n (%) n (%)
Single detections 
  All HRV 126 (13.1)‡ 328 (7.6) 1.1 (1.0 to  1.2);  0.22 8 (−5 to  20)
  HRV-A 57 (6.0) 122 (2.8) 1.2 (1.0 to  1.5);  0.11 17 (−4 to  34)
  HRV-B 8 (0.8) 41 (1.0) 0.8 (0.4 to  1.5);  0.43 −31 (−157 to  33)
  HRV-C 68 (7.1) 137 (3.2) 1.3 (1.1 to  1.6);  0.01 22 (5 to 36)
  IFV-A 2 (0.2) 2 (0.0) 1.6 (0.4, to 5.7);  0.50 36 (−131 to 82)
  IFV-B 0 (0.0) 2 (0.0) 0.0 (0.0 to  0.0); <0.001 0 (0 to  0)
  PIV-1 2 (0.2) 1 (0.0) 2.5 (0.8 to 7.8);  0.13 59 (−28 to  87)
  PIV-2 1 (0.1) 0 (0.0) n/c n/c
  PIV-3 10 (1.0) 11 (0.3) 2.0 (1.2 to  3.3);  0.006 50 (18 to  70)
  RSV-A 15 (1.6) 14 (0.3) 3.0 (2.1 to  4.5); <0.001 67 (51 to  78)
  RSV-B 8 (0.8) 3 (0.1) 3.2 (1.8 to  5.5); <0.001 68 (45 to  82)
  HCoV-OC43 9 (0.9) 8 (0.2) 2.3 (1.4 to  3.8);  0.001 56 (29 to 73)
  HCoV-NL63 7 (0.7) 8 (0.2) 1.7 (0.9 to  3.3);  0.10 42 (−10 to  70)
  HCoV-229E 1 (0.1) 4 (0.1) 1.2 (0.2 to  7.7);  0.83 19 (−407 to 87)
  HCoV-HKU1 2 (0.2) 10 (0.2) 0.8 (0.2 to  2.9);  0.71 −28 (−376 to  66)
  HMPV 6 (0.6) 4 (0.1) 3.2 (1.7 to  6.1); <0.001 69 (43  to  83)
  AdV 5 (0.5) 16 (0.4) 1.0 (0.4 to  2.5);  0.96 −2 (−156 to  59)
  WU-PyV 5 (0.5) 15 (0.3) 1.4 (0.6 to 3.5);  0.48 28 (−80 to  71)
  KI-PyV 8 (0.8) 34 (0.8) 1.2 (0.7 to  2.2);  0.55 17 (−53 to  56)
  HBoV-1 10 (1.0) 31 (0.7) 1.3 (0.8 to  2.2);  0.33 24 (−30 to  55)
  Any virus 217 (22.6) 491 (11.4) 1.4 (1.2 to  1.5); <0.001 27 (18 to  35)
New codetections§
  ≥2 viruses 58 (6.0) 62 (1.4) 2.2 (1.7 to  3.0); <0.001 55 (41 to  66)
Statistically significant risk ratios and attributable fractions have been highlighted in bold.
*Adjusted for repeated measures within children using sandwich estimators.
†CI for attributable fractions were calculated from CI  for corresponding risk ratios.
‡Individual HRV species do not add up to ‘all HRV’ detections because of a combination of more than one HRV species detected within the same LRTI episode, or single new virus 
detection episodes where HRV-positive specimens could not be sequenced.
§Includes 110 (51 symptomatic) new codetections and another 10 codetections with 2 and 3 viruses codetected, respectively where at least one codetected virus was a new 
detection.
AdV, adenovirus;   HBoV-1, human bocavirus-1; HCoV, human coronavirus; HMPV, human metapneumovirus; HRV, human rhinovirus; IFV, influenza virus; KI-PyV, KI 
polyomavirus; LRTI, lower respiratory tract infection;  n/c, not calculable as there were no cases in the asymptomatic group;, PIV, parainfluenza virus; RSV, respiratory syncytial 
virus; WU-PyV, WU polyomavirus. 
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contrast, HCoV-229E, HCoV-HKU1, WU-PyV, KI-PyV, and 
HBoV-1 were frequently detected in asymptomatic periods and 
had low point estimates for AFE, indicating they were less likely 
to have caused the ARI.
Of the total 1641 ARIs, 111 (6.8%) did not have swabs 
submitted during the ARI episode, including swabs taken 
7 days before or 7 days after the last day of the illness. Of the 
remaining 1530 ARIs, 1154 (75.4%) ARIs (935 (81%) URTI, 
219 (19.0%) LRTI) had ≥1 swabs with a virus detected during 
this period.
RSV and HMPV were more strongly associated with LRTI 
than asymptomatic detections (table 4), with higher risk ratios 
than other viruses. While significant, the association between 
LRTI and HRV-C, HCoV-OC43 and PIV-3 detection was 
weaker. Interestingly, codetected specimens had among the 
strongest AFE values for both ARIs and LRTIs (tables 3 and 4), 
with HRV the most frequently detected virus group, usually 
in combination with DNA viruses (see online supplementary 
E-table 3).
To investigate the sensitivity of results from including 
lesser quality swabs, we reanalysed the data by excluding 346 
virus-positive swabs of lesser quality, and found minimal change 
to the AFEs calculated in tables 3 and 4 (see online supplemen-
tary E-table 2).
Viruses and association with risk factors
Independent risk factors associated with symptomatic rather 
than asymptomatic VDEs, included increasing age, particu-
larly after 6 months, and virus infections during non-summer 
seasons (table 5). The regression model revealed childcare 
attendance was also independently associated with higher 
rates of VDEs, both symptomatic and asymptomatic, but no 
other risk factors were found to be associated with asymptom-
atic VDEs.
DISCUSSION
Healthy children in the ORChID community-based birth cohort 
experienced an incidence rate of 978 new VDEs per 100 child-
years during the first 2 years of life, with HRV playing a domi-
nant role. Overall, respiratory viruses were detected by PCR in 
regular weekly swabs at least once during 75% of ARIs, while 
in asymptomatic periods 23% of weekly nasal swabs were 
positive by PCR for respiratory viruses, accounting for 33% 
of all new VDEs. We demonstrated evidence of attribution for 
ARIs by RNA viruses, which included HRV (HRV-A, HRV-C), 
influenza (IFV-A), parainfluenza (PIV-1, PIV-3), RSV (RSV-A, 
RSV-B), HCoV (HCoV-OC43, HCoV-NL63) and HMPV; and 
AdV as the single DNA virus representative. All these viruses 
were detected significantly more often in children with an 
ARI than during asymptomatic periods and had statistically 
significant positive AFEs. The largest association was observed 
for RSV and HMPV, both of which were more strongly asso-
ciated with LRTIs than other respiratory viruses. Increasing 
age ≥6 months, non-summer months and childcare attendance 
were independent risk factors for symptomatic VDEs. Age as 
a host risk factor for symptomatic infection is also noted in 
other studies,23 and is presumably due to protection afforded 
by maternal transplacental and breastmilk antibodies in the 
very young.24 Environmental risk factors of season and child-
care attendance for ARIs may be related to the intensity and 
opportunity for exposure in these settings experienced by 
young children.10 25R
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The virus-specific attribution of ARIs was quantified by 
identifying VDEs during asymptomatic periods and calcu-
lating the virus-specific AFE, an infrequently reported metric 
for helping to determine the relative causal roles of different 
viruses at a population level. A limitation of the AFE approach 
is that it cannot inform on the aetiology at an individual level: 
in individual cases it does not differentiate between those with 
a true positive test identifying the virus responsible for the 
ARI and those with a false positive result from asymptomatic 
virus shedding. Nevertheless, knowing the AFE for respira-
tory viruses can help inform clinicians on the likely clinical 
significance of detecting one or more viruses in nasal swab 
specimens taken from infants or young children during an 
ARI episode, by assigning the group aetiological fraction for 
viruses detected in that child. Importantly, AFE estimates can 
be applied to studies of ARIs in different settings to estimate 
the true burden of disease in the community, thus informing 
which viruses should be prioritised in future public health 
policies and interventions.
Most previous studies have overestimated AFE values by using 
ORs, rather than RRs, in calculations.5 6 8 9  ORs  overestimate 
the effect size when the event is not rare, as occurs with ARIs 
in children. These studies are principally cross-sectional, hospi-
tal-based and often have poorly matched controls. Consequently, 
our estimates of AFE being lower than reported elsewhere is not 
surprising, and, we believe, are likely to provide more accurate 
estimates of the ARI and LRTI burden attributable to these 
viruses in the broader paediatric population.
The proportion of asymptomatic infections in our study high-
lights the risks of extrapolating hospital-based data from sick 
children to the community setting. Previously, the significance 
of detecting viruses by PCR was tempered by concerns that this 
may be from an incubating or unrelated subclinical infection or 
represent continued virus nucleic acid shedding from a recent 
ARI that has resolved. The intensive longitudinal specimen and 
symptom sampling from our cohort, as well as the definitions 
of VDEs and symptomatic VDEs used, helped identify nascent 
and subclinical infections. In this context, our observations 
emphasise the frequency of subclinical infections by respiratory 
viruses in young children, who when otherwise well, may act 
as important ‘silent’ reservoirs of infection. Similar observations 
and conclusions were reported recently in a household study 
involving both child and adult contacts of symptomatic cases 
of laboratory-confirmed influenza.26 Nevertheless, in addition 
to influenza, established viruses, such as HRV, PIV-3, RSV, and 
HMPV are also important community respiratory pathogens, 
especially the latter two viruses, and potential candidates for 
vaccine and other therapeutic interventions.27 This contrasts 
with the novel DNA viruses, HPyVs and HBoV-1, which have 
low AFEs calculated for both ARIs and LRTIs, despite their 
higher detection rates.28 29 However, as suggested by this cohort, 
synergy may exist between multiple viruses causing ARIs. Unex-
pectedly, this involved mostly HRV and DNA viruses, and this 
finding warrants further study.
Strengths and limitations
The 78% of expected child-days and 68% of expected swab 
returns was a very good retention rate given the intensive and 
prolonged nature of the study for participating families. Analysis 
of incidence rates of ARI in participants that withdrew from the 
study at different periods showed no clear association between 
time of dropout and ARI incidence. Regular parent-collected nasal 
swabs avoids the need for home visits by research staff or clinic 
attendance during an ARI, minimising possible biased estimates of 
ARI events and specimen availability from losing families failing to 
seek healthcare. Moreover, regular weekly nasal swab collections 
increase the likelihood of virus detections during an ARI episode 
rather than relying simply on results from a single specimen. 
Our previous work found that with sensitive PCR techniques, 
parent-collected nose or nose-throat swabs sent to the laboratory 
by standard mail had comparable sensitivity to nasopharyngeal 
swabs obtained by healthcare workers.18 19 30 Longitudinal data 
collection also allows assessment of asymptomatic status by consid-
ering past and future illness history, as some viruses are detectable 
days before and after ARI symptoms develop,31 and are therefore 
less likely to yield false-positive findings.
There are also some important limitations to consider. To 
reduce the chances of false-negative test results,21 we excluded 
from analysis 2679 (23.9%) swabs where the internal control 
for human DNA, ERV-3, was either undetected or present at 
very low levels. We excluded both virus-positive and virus-neg-
ative swabs to avoid overestimating our incidence and preva-
lence rates. In addition, some viruses were detected rarely, in 
particular influenza, a finding reflected in other community 
studies,17 but nevertheless limiting our ability to provide precise 
AFE estimates for these agents. We also excluded codetections in 
individual virus assessments as multiple aetiological agents make 
individual contributions of each agent difficult to ascertain, but 
analysed them separately to look at the association patterns of 
individual viruses. Symptom information, other than doctor-di-
agnosed otitis media and pneumonia, captured by daily diaries 
was not validated. To maximise accuracy, parents were trained to 
recognise symptoms before commencing the study. While health-
care worker-validated symptoms would be ideal, a study of this 
scale is logistically challenging without parent participation. This 
study design has been used previously18 and with others have 
shown that parents can be trained to recognise symptoms of 
interest,18 often as reliably as healthcare professionals.32 33 Our 
rates of ARI, including those associated with wheeze, are compa-
rable with other community studies.34 35
Finally, as is common for these types of studies, families in our 
cohort were from more advantaged backgrounds and ARI episodes 
were predominantly of a mild-to-moderate nature.22 While many 
children in our study were first-born and from advantaged fami-
lies, factors thought to decrease the rate of ARIs, secular changes in 
Australia have led to an increased proportion of children from these 
families attending childcare at an earlier age than other sectors of 
the population. A slightly higher proportion (80%–85%) of our 
cohort attended some form of care by the age of 15–24 months, 
compared with 74% of children in the Australian population, with 
childcare attendance an independent risk factor for ARIs.25 More-
over, the incidence of ARIs in the ORChID cohort22 is comparable 
to other reports in this age group34 36 37 and RSV and HRV-associ-
ated ARIs approximate other community-based studies conducted 
in more temperate climates of Australia (Perth) and Europe.38–40 
Our findings for this cohort remain valid and provide important 
estimates on community respiratory virus exposures and ARIs in 
Australian children in a subtropical, urban setting.
CONCLUSIONS
Respiratory viruses, particularly HRV, were detected with remark-
able frequency in healthy Australian children in the first 2 years 
of life, with at least one-third of new VDEs unaccompanied by 
symptoms. With molecular methods used increasingly to detect 
respiratory viruses in young children, our study provides insights 
into supporting attribution for virus-specific ARIs in this age group 
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managed within the community. The established RNA respiratory 
viruses and AdV were more strongly associated with symptomatic 
than asymptomatic infections, while no such associations were 
found for the newly described DNA viruses, HPyVs and HBoV-1. 
These data emphasise the high community levels of HRV circu-
lating among children. Importantly, they also provide evidence to 
suggest that the current clinical trials of candidate RSV and HMPV 
vaccines seeking to protect infants against severe disease and hospi-
talisation might also deliver substantial health benefits for all young 
children within the community.27
Correction notice This article has been corrected since it was published Online 
First. Figure 2 has been updated to include the missing figure legend. 
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